Facilitated By

San Antonio Medical Foundation

A PHASE II, DOUBLE-BLIND, RANDOMIZED, THREE-WAY CROSSOVER, PLACEBO-CONTROLLED, PHARMACODYNAMIC STUDY OF CK-2017357 IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS ON STANDARD THERAPY

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Jackson,Carlayne E
Funded by
CYTOKINETICS
Research Start Date
Status
Inactive
Clinical Care
Drug Discovery
Neuroscience